Early inhibition of IL-17A with secukinumab in both murine and porcine models of CA/CPR significantly attenuated PCAS, including improved left ventricular ejection fraction, reduced neuronal apoptosis, and improved 72-hour survival (all <i>P</i> < 0.05), demonstrating multi-organ protective effects.<h4>Conclusions</h4>These findings demonstrate that CA induces a systemic inflammatory response that drives heart-brain injury and multi-organ dysfunction, and IL-17A acts as an inflammatory mediator in this process. This evidence concerns the gene IL17A and brain injury.